Key result
A high-risk Khorana score was associated with a significantly higher 6-month cumulative incidence of venous thromboembolism compared to a low-risk score (8.84% vs 1.56%) in Hispanic outpatients with solid tumors.
Why the study?
The Khorana risk score for prognosis of venous thromboembolism has been rarely explored in Hispanic populations.
Does the Khorana risk score predict venous thromboembolism and overall survival in Hispanic ambulatory patients with newly diagnosed solid tumours receiving chemotherapy?
Cohort (n=708)
No
Does the Khorana risk score predict venous thromboembolism and overall survival in Hispanic ambulatory patients with newly diagnosed solid tumours receiving chemotherapy?
Absolute Event Rate: 8.84% vs 1.56%
p-value: p=0.0178
The Khorana risk score is a valid prognostic tool for predicting venous thromboembolism and overall mortality in Hispanic patients with solid tumors undergoing chemotherapy.
Supports VTE risk stratification in Hispanic cancer outpatients; extends Khorana validation to this group but leaves practice change open pending RCTs.
Background: The Khorana risk score (KRS) for prognosis of venous thromboembolism (VTE) has been rarely explored in Hispanic populations. Objective: To determine the value of the KRS for prediction of VTE and overall survival (OS) among Hispanic individuals with cancer. Methods: We retrospectively evaluated all outpatients with newly diagnosed solid tumours receiving systemic chemotherapy in Hospital San Juan Dios, San José, Costa Rica, from January to December 2021. The 6-month cumulative VTE incidence according to the KRS categories was estimated using the Fine & Gray competing risk model. A Kaplan-Meier analysis was used to compare OS among KRS categories. The Cox regression analysis was performed to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI). The receiver operating characteristic (ROC) analysis was performed to identify the optimal cutoff value to predict VTE during follow-up. Results: < 0.001, for the comparison of 'high-risk' and 'low-risk' KRS). Conclusions: The KRS is a valid tool to predict VTE and mortality in a cohort of Hispanic outpatients with newly diagnosed solid tumours.
No takes yet. Share an insight, caveat, or question.
Ramos-Esquivel et al. (2022) conducted a cohort in Solid tumors (n=708). High-risk Khorana score vs. Low-risk Khorana score was evaluated on 6-month cumulative incidence of venous thromboembolism (p=0.0178). A high-risk Khorana score was associated with a significantly higher 6-month cumulative incidence of venous thromboembolism compared to a low-risk score (8.84% vs 1.56%) in Hispanic outpatients with solid tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: